our Premium Content: News alerts, weekly reports and conference planners

GENE:

RPS6KB1 (Ribosomal Protein S6 Kinase B1)

News alerts, weekly reports and conference planners

3ms

Discovery of actionable drug targets to enhance T-cell infiltration and immune checkpoint blockade efficacy in pleural mesothelioma. (PubMed, Lung Cancer)

This comprehensive transcriptomic characterization of T-cell exclusion in PM reveals that targeting cilium-based Hedgehog signaling, in addition to multiple other actionable drug targets, could enhance the efficacy of ICB treatment in PM.

3 months ago

Journal • Checkpoint inhibition • PD(L)-1 Biomarker • IO biomarker

HER-2 (Human epidermal growth factor receptor 2) • SMO (Smoothened Frizzled Class Receptor) • ACVR1 (Activin A Receptor Type 1) • RPS6KB1 (Ribosomal Protein S6 Kinase B1) • CMTM4 (CKLF Like MARVEL Transmembrane Domain Containing 4) • KDM5B (Lysine Demethylase 5B) • SOX4 (SRY-Box Transcription Factor 4) • BMPR1B (Bone Morphogenetic Protein Receptor Type 1B)

Opdivo (nivolumab) • Yervoy (ipilimumab)

4ms

An integrated environmental toxicity risk assessment framework combining deep learning and molecular simulation: A case study on pyrethrins and breast cancer. (PubMed, Biochem Biophys Rep)

This integrative methodology supports environmental exposure monitoring and toxicological policy development. The open-source, containerized analytical toolchain developed herein is highly extensible and adaptable for future toxicological evaluations of other natural compounds and emerging environmental pollutants.

4 months ago

Journal

ER (Estrogen receptor) • CTNNB1 (Catenin (cadherin-associated protein), beta 1) • RPS6KB1 (Ribosomal Protein S6 Kinase B1)

ER positive

5ms

Gene fusion detection in long-read transcriptome sequencing data with GFvoter. (PubMed, BMC Genomics)

Overall, our findings show that GFvoter can accurately identify gene fusions from long-read RNA-seq data, which has the potential to improve cancer diagnosis and treatment. GFvoter is available at https://github.com/xiaolan-z/GFvoter .

5 months ago

Journal

RPS6KB1 (Ribosomal Protein S6 Kinase B1) • VMP1 (Vacuole Membrane Protein 1)

5ms

Novel kinase-activating genetic events in non-small cell lung carcinomas. (PubMed, Explor Target Antitumor Ther)

ROS1, LTK, and FGFR4 high-level overexpression was observed in 1 out of 89 tumors each. This study demonstrates the scarcity of yet unknown kinase-activating alterations in NSCLCs.

5 months ago

Journal

EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • NRAS (Neuroblastoma RAS viral oncogene homolog) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2) • FGFR4 (Fibroblast growth factor receptor 4) • LTK (Leukocyte Receptor Tyrosine Kinase) • RPS6KB1 (Ribosomal Protein S6 Kinase B1) • CLIP1 (CAP-Gly Domain Containing Linker Protein 1) • KAT6B (Lysine Acetyltransferase 6B) • VMP1 (Vacuole Membrane Protein 1)

6ms

Oxocrebanine inhibits the proliferation of hepatocellular carcinoma cells by promoting apoptosis and autophagy. (PubMed, World J Gastrointest Oncol)

Oxocrebanine can inhibit the proliferation of human hepatocellular carcinoma cells by promoting apoptosis and inducing autophagy in vitro and in vivo.

6 months ago

Journal • IO biomarker

BCL2 (B-cell CLL/lymphoma 2) • MCL1 (Myeloid cell leukemia 1) • CASP3 (Caspase 3) • EIF4EBP1 (Eukaryotic translation initiation factor 4E binding protein 1) • RPS6KB1 (Ribosomal Protein S6 Kinase B1)

7ms

S6K1 overexpression enhances autophagy in breast cancer cells by inducing the translation of CLU. (PubMed, Chin Med J (Engl))

This study demonstrated that the overexpression of S6K1 promoted autophagy in breast cancer cells by facilitating the translation of the autophagy-related gene CLU.

7 months ago

Journal

RPS6KB1 (Ribosomal Protein S6 Kinase B1) • CLU (Clusterin) • RPS6 (Ribosomal Protein S6)

8ms

Comprehensive genomic profiling reveals a unique genomic landscape in solid tumors in an Indian cancer cohort of 1000 patients: a single institutional experience. (PubMed, Sci Rep)

The overall change in therapy based on CGP in the clinical cohort was 43%, which was greater in patients enrolled for MTB than in patients who had not undergone MTB. At the interim analysis, with a median follow-up of 18 months (range 12-24 months) after the change in therapy as per genomics report, 97 patients (71%) were found to be alive thus establishing the importance of CGP and MTB in personalized genomics-driven treatment.

8 months ago

Journal • Tumor mutational burden • BRCA Biomarker • PARP Biomarker • IO biomarker

EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • TMB (Tumor Mutational Burden) • MSI (Microsatellite instability) • EML4 (EMAP Like 4) • HRD (Homologous Recombination Deficiency) • ARID1A (AT-rich interaction domain 1A) • PDGFRA (Platelet Derived Growth Factor Receptor Alpha) • FGFR (Fibroblast Growth Factor Receptor) • BRCA (Breast cancer early onset) • ARID2 (AT-Rich Interaction Domain 2) • RPS6KB1 (Ribosomal Protein S6 Kinase B1) • NTRK (Neurotrophic receptor tyrosine kinase) • VMP1 (Vacuole Membrane Protein 1)

BRCA mutation

9ms

Activating autophagy to eliminate toxic protein aggregates with small molecules in neurodegenerative diseases. (PubMed, Pharmacol Rev)

Moreover, we underscore the activation of autophagy as a potential therapeutic strategy across different NDs and small molecules capable of activating autophagy pathways, such as rapamycin targeting the mTOR pathway to clear α-synuclein and Sertraline targeting the AMPK/mTOR/RPS6KB1 pathway to clear Tau, to further illustrate their potential in NDs' therapeutic intervention. It also elucidates the fascinating interrelationships between toxic proteins and the process of autophagy of "chasing and escaping" phenomenon. Moreover, the review further discusses the progress utilizing small molecules to activate autophagy to improve the efficacy of therapies for neurodegenerative diseases by removing toxic protein aggregates.

9 months ago

Review • Journal

TARDBP (TAR DNA Binding Protein) • RPS6KB1 (Ribosomal Protein S6 Kinase B1)

sirolimus

9ms

Targeting p70S6K1 Inhibits Glycated Albumin-Induced Triple-Negative Breast Cancer Cell Invasion and Overexpression of Galectin-3, a Potential Prognostic Marker in Diabetic Patients with Invasive Breast Cancer. (PubMed, Biomedicines)

Further in silico validation analyses revealed increased gene expression of galectin-3 in DM TNBC patients, resulting in poor overall survival and disease-free survival. Targeting p70S6K1 may present a valuable therapeutic strategy, while galectin-3 could serve as a potential prognostic biomarker for invasive BC progression in DM patients.

9 months ago

Journal

LGALS3 (Galectin 3) • RPS6KB1 (Ribosomal Protein S6 Kinase B1) • RPS6 (Ribosomal Protein S6) • CTSD (Cathepsin D)

9ms

A Novel CLTC::RPS6KB1 Fusion in a Poorly Differentiated Carcinoma Involving the Lung and Mediastinum. (PubMed, Int J Surg Pathol)

Herein, we present a poorly differentiated carcinoma involving lung and mediastinum. Next generation sequencing-based RNAseq identified a novel fusion, CLTC::RPS6KB1, while no other known drivers were present.

9 months ago

Journal

CLTC (Clathrin Heavy Chain) • RPS6KB1 (Ribosomal Protein S6 Kinase B1)

9ms

Tumor gene expression signatures associated with outcome in large B-cell lymphoma treated with CD19-directed CAR T-cell therapy (axicabtagene ciloleucel). (PubMed, Front Oncol)

The 6-GES was reduced, whereas the 17-GES was elevated at progression post axi-cel, consistent with the notion that these signatures represent features relevant for response and resistance to CAR T-cell therapy. Our transcriptomic analysis identified gene expression signatures potentially predictive of outcome with CD19-directed CAR T-cell therapy, and these findings are informative for risk stratification and development of next-generation products.

9 months ago

Journal • IO biomarker

ER (Estrogen receptor) • BCL2 (B-cell CLL/lymphoma 2) • ARID1A (AT-rich interaction domain 1A) • CD19 (CD19 Molecule) • KIR3DL2 (Killer Cell Immunoglobulin Like Receptor Three Ig Domains And Long Cytoplasmic Tail 2) • NBN (Nibrin Nijmegen Breakage Syndrome 1 (Nibrin)) • CCL2 (Chemokine (C-C motif) ligand 2) • RPS6KB1 (Ribosomal Protein S6 Kinase B1) • SLC16A1 (Solute Carrier Family 16 Member 1) • CCL22 (C-C Motif Chemokine Ligand 22) • SOX11 (SRY-Box Transcription Factor 11) • TNFSF4 (TNF Superfamily Member 4) • DUSP5 (Dual Specificity Phosphatase 5) • KLRB1 (Killer Cell Lectin Like Receptor B1) • NKG2D (killer cell lectin like receptor K1) • SERPINA9 (Serpin Family A Member 9) • SIGLEC5 (Sialic Acid Binding Ig Like Lectin 5)

Yescarta (axicabtagene ciloleucel)

9ms

Orchestrating Intracellular Calcium Signaling Cascades by Phosphosite-Centric Regulatory Network: A Comprehensive Analysis on Kinases CAMKK1 and CAMKK2. (PubMed, OMICS)

Further, CAMKK2 was identified as a primary orchestrator in mediating intracellular calcium signaling cascades compared to CAMKK1 based on coregulation patterns of phosphosites from proteins involved in the calcium signaling pathway. These molecular details shed promising insights into the pathophysiology of several diseases such as cancers and psychiatric disorders associated with kinase activity dysregulations of CAMKK2 and further open the avenue for novel PTM-directed therapeutic strategies to regulate CAMKK2.

9 months ago

Journal

RPS6KB1 (Ribosomal Protein S6 Kinase B1) • CAMKK1 (Calcium/Calmodulin Dependent Protein Kinase Kinase 1)